|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
There was no difference in the genotype frequencies of BRAF and TSHR between PTC patients and control subjects, suggesting no contribution of BRAF or TSHR polymorphisms to the susceptibility to PTC.
|
31658048 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The results showed that the elevated CK-19 expression, and the presence of BRAF mutations and RET/PTC rearrangements were indicators of multifocal PTC in HT, suggesting the need for total bilateral thyroidectomy.
|
31497359 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
BRAF wild type PTC tissue of 56 patients was analyzed using two established methods: hybrid-specific RT-PCR for the predominant rearrangement RET/PTC1 and fluorescent in situ hybridization (FISH).
|
30472213 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma.
|
30924609 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E and Retinoic Acid in Radioiodine-Refractory Papillary Thyroid Cancer.
|
30396219 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Accurate screening for BRAF mutation may contribute to improving the risk stratification of PTC.
|
30988823 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We analyzed mutations of BRAF (V600E) and TERT promoter (C228T, C250T) in tumor DNA from 141 patients (75 with classical variant PTC, CVPTC; 66 with follicular variant PTC, FVPTC) recruited through a multi-center study.
|
31454788 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We conclude that coexisting BRAF V600E and TERT mutations in patients with PTC are associated with poor initial prognostic factors and clinical course and may be useful for predicting a worse response to therapy, recurrence, and poorer outcome than in patients without the above mutations.
|
31305897 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
We investigate programmed cell death 4 (PDCD4) immunohistochemical expression in 125 consecutive PTCs with median follow-up of 75.3 months (range, 15-98 months) to verify the possible correlation between BRAF status and correlate the classical clinicopathological prognostic factors and PTC outcome with PDCD4 expression.
|
31692513 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
|
30875124 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
We also monitored the proliferation, apoptosis and migration ability of human papillary-thyroid carcinoma (BCPAP) cells at different iodine concentrations and their association with changes in autophagy and BRAF kinase activity of BCPAP cells at high iodine levels (10<sup>-3</sup> mol/l).
|
31563816 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
BRAF expression was not higher in PTC with acromegaly patients compared to PTC patients without acromegaly.
|
29890543 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
|
31758408 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Overall, 74.9% (155/207) of the PTC nodules had the BRAFV600E mutation, while 25.1% (52/207) had the wild-type BRAF allele.
|
31452778 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
38.2% of human PTCs displayed high expression of AXL that positively correlated with RAI-refractoriness and disease persistence or recurrence, especially when combined with v-raf murine sarcoma viral oncogene homolog B(BRAF) V600E mutation.
|
31181609 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
Groups of BRAF-like, BRAF<sup>V600E</sup>-positive cPTCs and fvPTCs that are homogenous in regard to histopathology, driver mutation and BRS were found to be highly heterogenous in terms of gene expression patterns.
|
31478162 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Seven of the 9 indeterminate and suspicious cases with the BRAF V600E mutation had surgical follow-up, and they were all confirmed to be PTC.
|
30620446 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
Biomarker
|
disease |
BEFREE |
A total of 237 patients had BRAF (+) PTCs, whereas 253 had BRAF (-) PTCs.
|
30592330 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We further discuss a case with a single BRAF V600E cytological mutant lacking a postoperative PTC diagnosis and discuss the limitations of BRAF V600E detection using puncture elution fluid.
|
31529211 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We describe a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma (PTC-FLS) that contained the rare BRAF c.1799_1801delTGA (p.V600_K601delinsE) mutation, which has not previously been reported in this tumour, as well as the CTNNB1 c.133T>C (p.S45P) mutation.
|
31327063 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
All but one BRAF-mutated PTC had the BRAFV600E mutation.
|
30294871 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Our study aimed to investigate the performance of droplet digital PCR (ddPCR) in detecting BRAF V600E mutation in FNA samples from PTC patients.
|
30682328 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We showed that the disrupted novel miRNAs have diagnostic and prognostic potential, and were associated with BRAF mutation, a frequent alteration related to more aggressive PTC.
|
30842597 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
This is the first reported case of an acquired KRAS-activating mutation that developed during treatment with BRAF and MEK inhibition in a patient with BRAF-mutated PTC.
|
31085763 |
2019 |
|
Papillary thyroid carcinoma
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
PTC with BRAF V600E mutation showed higher expression of ATX, LPA1, LPA2, and LPA3 than PTC without BRAF V600E mutation (p < 0.001).
|
31455351 |
2019 |